Antibodies targeting NKG2A and uses thereof

A novel NKG2A antibody with enhanced affinity and specificity is developed to improve NK cell inhibition and tumor targeting, addressing the limitations of existing antibodies by increasing therapeutic efficacy in cancer and autoimmune disease treatment.

JP7590034B2Active Publication Date: 2024-11-26BIOHENG THERAPEUTICS LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2023530941
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-11-23
Filing Date
2021-11-18
Publication Date
2024-11-26
Estimated Expiration
2041-11-18

AI Technical Summary

Technical Problem

Existing antibodies targeting NKG2A do not effectively enhance the killing activity of tumor-specific lymphocytes, and there is a need for improved antibodies with higher affinity and specificity for therapeutic applications.

Method used

Development of a new NKG2A antibody with specific CDR sequences and back-mutation variants, which can be used in multispecific formats, chimeric receptors, and immune cell modifications to enhance NK cell inhibition and tumor targeting.

Benefits of technology

The new NKG2A antibody demonstrates higher affinity and better suppressive effects on NK cell killing, enhancing therapeutic efficacy in treating diseases such as cancer and autoimmune disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007590034000003
    Figure 0007590034000003
  • Figure 0007590034000004
    Figure 0007590034000004
  • Figure 0007590034000005
    Figure 0007590034000005
Patent Text Reader

Abstract

The present invention provides antibodies that target NKG2A, as well as multispecific antibodies, chimeric receptors, antibody conjugates, pharmaceutical compositions and kits containing the same, and their use in the prevention, treatment and diagnosis of diseases associated with NKG2A expression.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of immunotherapy, more specifically to antibodies targeting NKG2A and their use in the prevention, treatment and diagnosis of diseases. [Background technology]

[0002] Natural killer (NK) cells are a very important type of lymphocyte in the body, and play important roles in both innate and adaptive immunity. There are two types of surface receptors on the surface of NK cells, which can be divided into inhibitory and activating types according to their functions, and mediate different recognition modes of NK cells and transmit different activation and inhibitory signals. The CD94 / NKG2 family is a receptor family that has been widely studied, and mainly includes members such as NKG2A, NKG2B, NKG2C, NKG2D, NKG2E, NKG2F, and NKG2H. Among them, NKG2A belongs to the inhibitory receptor, and its ligand is the non-classical major histocompatibility complex class I molecule HLA-E. After HLA-E molecules expressed on target cells are bound to NKG2A, the killing function of NK cells has an inhibitory effect. Therefore, antibodies targeting CD94 / NKG2A may improve the killing activity of tumor-specific lymphocytes against tumor cells.

[0003] Several anti-NKG2A antibodies have been described in the art. For example, Sivori et al. (Eur J Immunol 1996;26:2487-92) refer to the mouse anti-NKG2A antibody Z270, Carretero et al. (Eur J Immunol 1997;27:563-7) describe the mouse anti-NKG2A antibody Z199 (now commercially available from Beckman Coulter, Inc., product number IM2750, USA), Vance et al. (J Exp Med 1999;190:1801-12) refer to the murine anti-mouse NKG2-antibody 20D5 (now commercially available from BD Biosciences Pharmingen, catalog number 550518, USA), and US Patent Application Disclosure 20030095965 describes the mouse antibody 3S9, which is said to bind to NKG2A, NKG2C and NKG2E.

[0004] The present invention aims to provide a novel antibody that targets NKG2A and its use in the prevention, treatment and diagnosis of diseases. Summary of the Invention

[0005] In a first aspect, the present invention provides an antibody targeting NKG2A, comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises CDR-L1 shown in SEQ ID NO: 1, CDR-L2 shown in SEQ ID NO: 2, and CDR-L3 shown in SEQ ID NO: 3; the heavy chain variable region comprises CDR-H1 shown in SEQ ID NO: 4, CDR-H2 shown in SEQ ID NO: 5, and CDR-H3 shown in SEQ ID NO: 6, wherein the light chain variable region has M at the 21st amino acid and T at the 85th amino acid, and the heavy chain variable region has M at the 34th amino acid, A at the 49th amino acid, P at the 61st amino acid, and T at the 97th amino acid.

[0006] In one embodiment, the light chain variable region has S or T at amino acid 22, I or V at amino acid 58, and L or V at amino acid 104.

[0007] In a preferred embodiment, the light chain variable region of the NKG2A antibody has at least 90% identity to an amino acid sequence set forth in one selected from SEQ ID NOs: 10 and 13, or has one or several (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, up to 7, up to 6, up to 5, up to 4, up to 3, up to 2) amino acid conservative modifications compared to SEQ ID NOs: 10 and 13, and the heavy chain variable region has at least 90% identity to an amino acid sequence set forth in SEQ ID NO: 11, or has one or several (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, up to 7, up to 6, up to 5, up to 4, up to 3, up to 2) amino acid conservative modifications compared to SEQ ID NO: 11. More preferably, the NKG2A antibody comprises a light chain variable region set forth in one selected from SEQ ID NOs: 10 and 13, and a heavy chain variable region set forth in SEQ ID NO: 11.

[0008] In one embodiment, the amino acid sequence of the NKG2A antibody is selected from SEQ ID NOs:12 and 14.

[0009] The present invention further provides a nucleic acid molecule encoding the above-mentioned NKG2A antibody. Thus, in one embodiment, the nucleic acid molecule encoding the NKG2A antibody has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a nucleotide sequence selected from SEQ ID NOs: 16 to 17, and the encoded NKG2A antibody is capable of specifically binding to NKG2A. Preferably, the nucleic acid molecule encoding the NKG2A antibody is selected from SEQ ID NOs: 16 to 17.

[0010] In another aspect, the present invention further provides a multispecific antibody (preferably a bispecific or trispecific antibody) comprising the above-described NKG2A antibody and one or more second antibodies or antigen-binding portions thereof that specifically bind to other antigens.

[0011] In one embodiment, the second antibody or antigen-binding portion thereof may have any antibody or antibody fragment format, such as, for example, a full length antibody, Fab, Fab', (Fab')2, Fv, scFv, scFv-scFv, microantibody, diabody or sdAb.

[0012] The present invention further provides vectors of nucleic acid molecules encoding the above-mentioned NKG2A antibodies or multispecific antibodies, and host cells expressing said NKG2A antibodies or multispecific antibodies.

[0013] In another aspect, the present invention further provides a chimeric receptor comprising one or more NK inhibitory ligands, a transmembrane domain and a signaling domain, wherein the NK inhibitory ligand comprises an NKG2A antibody as described above, or a multispecific antibody containing the NKG2A antibody, and the signaling domain comprises one or more costimulatory domains.

[0014] In one embodiment, the chimeric receptor comprises two NK inhibitory ligands, of which the first NK inhibitory ligand is the NKG2A antibody described above and the second NK inhibitory ligand is selected from (1) an antibody or fragment thereof that targets an NK inhibitory receptor, such as LIR1, NKG2B, CD94, LIR2, LIR3, KIR2DL1, KIR2DL2 / 3, KIR3DL1, CEACAM1, LAIR1, and KLRG1, or (2) HLA-E, HLA-F, HLA-G, cadherin, collagen, OCIL, sialic acid, PD-L1, PD-L2, CD155, CD112, CD113, Gal-9, FGL1, and NK inhibitory receptor binding domains contained therein.

[0015] In one embodiment, the signaling domain in a chimeric receptor of the invention is comprised of one or more costimulatory domains, i.e. does not include primary signaling domains, such as those from FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b, and CD66d.

[0016] In another embodiment, the signaling domain of a chimeric receptor of the invention may comprise a primary signaling domain, such as, for example, the CD3 zeta intracellular domain.

[0017] The present invention further provides a nucleic acid molecule encoding a chimeric receptor targeting NKG2A as defined above, and a vector comprising said nucleic acid molecule.

[0018] The present invention further provides modified immune cells that express a chimeric receptor comprising an NKG2A antibody of the present invention, in which expression of at least one MHC-associated gene is suppressed or silenced.

[0019] In one embodiment, the MHC-related gene is selected from HLA-A, HLA-B, HLA-C, B2M, HLA-DPA, HLA-DQ, HLA-DRA, TAP1, TAP2, LMP2, LMP7, RFX5, RFXAP, RFXANK, CIITA, and combinations thereof, preferably selected from HLA-A, HLA-B, HLA-C, B2M, RFX5, RFXAP, RFXANK, CIITA, and combinations thereof.

[0020] In one embodiment, the modified immune cells expressing a chimeric receptor comprising an NKG2A antibody of the present invention further comprise at least one TCR / CD3 gene, the expression of which is inhibited or silenced, examples of which include, for example, TRAC, TRBC, CD3γ, CD3δ, CD3ε, CD3ζ.

[0021] In one embodiment, the modified immune cells provided herein further express a chimeric antigen receptor that targets a tumor antigen.

[0022] In one embodiment, the immune cell is selected from a T cell, a NK cell, a NKT cell, a macrophage, or a dendritic cell.

[0023] In another aspect, the present invention further provides an antibody conjugate comprising an NKG2A antibody as defined in the present invention and a second functional structure, wherein said second functional structure is selected from an Fc, a radioisotope, a structural moiety that extends half-life, a detectable marker and a drug.

[0024] In one embodiment, the half-life extending structural moiety is selected from albumin binding structures, transferrin binding structures, polyethylene glycol molecules, recombinant polyethylene glycol molecules, human serum albumin, fragments of human serum albumin, and white polypeptides (including antibodies) that bind to human serum albumin. In one embodiment, the detectable marker is selected from fluorophores, chemiluminescent compounds, bioluminescent compounds, enzymes, antibiotic resistance genes, and imaging agents. In one embodiment, the drug is selected from cytotoxins and immunomodulators.

[0025] In another aspect, the present invention further provides a detection kit comprising the antibody, multispecific antibody, antibody complex or chimeric receptor according to the present invention.

[0026] In another aspect, the present invention further provides a pharmaceutical composition comprising an antibody, chimeric receptor, multispecific antibody, engineered immune cell or antibody complex according to the invention, and one or more pharma- ceutically acceptable excipients.

[0027] In another aspect, the present invention further provides a method for treating, preventing or diagnosing a disease associated with NKG2A expression, comprising administering to a subject the antibody, chimeric receptor, multispecific antibody, antibody conjugate, modified immune cell or pharmaceutical composition described above.

[0028] Unless otherwise defined, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. NKG2A antibody

[0029] In the context of the present invention, a "Z199 antibody" is the murine anti-NKG2A antibody Z199 described in Carretero et al. (Eur J Immunol 1997;27:563-7), currently available commercially from Beckman Coulter, Inc. under product number IM2750. A "hZ199 antibody" is a humanized Z199 antibody, comprising a light chain variable region as set forth in SEQ ID NO:7 and a heavy chain variable region as set forth in SEQ ID NO:8, with the full length amino acid sequence set forth in SEQ ID NO:9.

[0030] The novel NKG2A antibody provided in the present invention is obtained by backmutation based on hZ199, and provides higher affinity and better inhibitory effect on NK cell killing.

[0031] As used herein, the term "antibody" has the broadest meaning as understood by those skilled in the art and includes monoclonal antibodies (including intact antibodies), polyclonal antibodies, multivalent antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments or synthetic polypeptides having one or more CDR sequences capable of exhibiting a desired biological activity. The antibodies of the present invention may be of any type (e.g., IgG, IgE, IgM, IgD, IgA, etc.) or subclass (e.g., IgG1, IgG2, IgG2a, IgG3, IgG4, IgA1, IgA2, etc.).

[0032] Typically, an intact antibody comprises two heavy chains and two light chains linked by disulfide bonds, with each light chain linked to its respective heavy chain by a disulfide bond, forming a "Y" shaped structure. Each heavy chain comprises a heavy chain variable region (VH) and a heavy chain constant region, where the heavy chain variable region comprises three complementarity determining regions (CDRs), such as CDR-H1, CDR-H2 and CDR-H3, and the heavy chain constant region comprises three constant domains, such as CH1, CH2 and CH3. Each light chain comprises a light chain variable region (VL) and a light chain constant region, where the light chain variable region comprises three CDRs, such as CDR-L1, CDR-L2 and CDR-L3, and the light chain constant region comprises one constant domain, CL. In the heavy / light chain variable regions, the CDRs are separated by more conserved framework regions (FR). The variable regions of the heavy / light chains are responsible for recognizing and binding to antigens, whereas the constant regions can mediate the binding of the antibody to host tissues or factors, including various cells of the immune system (e.g. effector cells) and the first component of the classical complement system.

[0033] The precise amino acid sequence boundaries of a given CDR or FR can be readily identified using a number of numbering schemes well known in the art, including, but not limited to, Kabat et al. (1991), "Sequences of Proteins of Immunological Interest," 5th ed. Public Health Service, National Institutes of Health, Bethesda, MD (the "Kabat" numbering scheme); Al-Lazikani et al., (1997) JMB 273, 927-948 (the "Chothia" numbering scheme); MacCallum et al., J. Mol. Biol. 262:732-745 (1996), "Antibody-antigen interactions: Contact analysis and binding sitetopography" J. Mol. Biol. 262, 732-745" (the "Contact" numbering scheme); and Lefranc MP et al., "IMG Tunique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains," DevComp Immunol, January 2003;27(1):55-77 ("IMGT" numbering scheme); Honegger A and Pluckthun A, "Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool," JMol Biol, June 8, 2001;309(3):657-70 ("Aho" numbering scheme); and Martin et al., "Modeling antibody hypervariable loops: a combined algorithm," PNAS, 1989,86(23):9268-9272 ("AbM" numbering scheme).

[0034] The boundaries of a given CDR or FR may vary depending on the protocol used for identification. For example, the Kabat scheme is based on structural comparisons, while the Chothia scheme is based on structural information. The numbers in the Kabat and Chothia schemes are based on the sequence lengths of the most common antibody regions, and different numbers are generated by placing certain insertions and deletions ("indels") at different positions. The Contact scheme is based on the analysis of complex crystal structures and is similar in many ways to the Chothia numbering scheme. The AbM scheme is a compromise between the Kabat and Chothia definitions and is the scheme used in Oxford Molecular's AbM antibody modeling software.

[0035] Thus, unless otherwise specified, the "CDR" of a given antibody or a region thereof (e.g., its variable region) should be understood to cover the CDRs defined by any of the above or other known schemes. For example, when a particular CDR (e.g., CDR3) is specified to include a given amino acid sequence, it should be understood that such CDR may have the sequence of the corresponding CDR (e.g., CDR3) defined by any of the above or other known schemes. Similarly, unless otherwise specified, the FR of a given antibody or a region thereof (e.g., its variable region) should be understood to cover the FRs defined by any of the above or other known schemes. Unless otherwise specified, the amino acid numbering in this specification is based on the Chothia scheme.

[0036] As used herein, the term "antibody fragment" or "antigen-binding portion" includes only a portion of an intact antibody, generally including the antigen-binding site of the intact antibody, thereby retaining the ability to bind to an antigen. Examples of antibody fragments in the present invention include, but are not limited to, Fab, Fab', F(ab')2, Fd fragment, Fd', Fv fragment, scFv, disulfide-bonded Fv (sdFv), the heavy chain variable region (VH) or light chain variable region (VL) of an antibody, linear antibodies, "double bodies" having two antigen-binding sites, single domain antibodies, nanobodies, natural ligands of said antigens or functional fragments thereof, etc. Thus, the "antibody" of the present invention covers the antibody fragments defined above.

[0037] "Single chain antibody" and "scFv" are used interchangeably herein and are antibodies in which the antibody heavy chain variable region (VH) and light chain variable region (VL) are linked by a linker. The optimal length and / or amino acid composition of the linker can be selected. The length of the linker obviously influences the folding and interaction conditions of the variable regions of the scFv. Indeed, the use of short linkers (e.g., between 5 and 10 amino acids) can prevent intrachain folding. For selection of linker size and composition, see, e.g., Hollinger et al., 1993 Proc Natl Acad. Sci. USA 90:6444-6448, U.S. Patent Application Publication Nos. 2005 / 0100543, 2005 / 0175606, 2007 / 0014794, and PCT Publication Nos. WO2006 / 020258 and WO2007 / 024715, which are incorporated herein by reference in their entireties. An scFv may comprise a VH and a VL linked in any order, e.g., VH-linker-VL or VL-linker-VH.

[0038] In a first aspect, the present invention provides an antibody targeting NKG2A, comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises CDR-L1 shown in SEQ ID NO: 1, CDR-L2 shown in SEQ ID NO: 2, and CDR-L3 shown in SEQ ID NO: 3; the heavy chain variable region comprises CDR-H1 shown in SEQ ID NO: 4, CDR-H2 shown in SEQ ID NO: 5, and CDR-H3 shown in SEQ ID NO: 6, wherein the 21st amino acid of the light chain variable region is M and the 85th amino acid is T, and the 34th amino acid of the heavy chain variable region is M, the 49th amino acid is A, the 61st amino acid is P, and the 97th amino acid is T.

[0039] In one embodiment, the light chain variable region has S or T at amino acid 22, I or V at amino acid 58, and L or V at amino acid 104.

[0040] In a preferred embodiment, the light chain variable region of the NKG2A antibody has at least 90% identity to an amino acid sequence set forth in one selected from SEQ ID NOs: 10 and 13, or has one or several (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, up to 7, up to 6, up to 5, up to 4, up to 3, up to 2) amino acid conservative modifications compared to SEQ ID NOs: 10 and 13, and the heavy chain variable region has at least 90% identity to an amino acid sequence set forth in SEQ ID NO: 11, or has one or several (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, up to 7, up to 6, up to 5, up to 4, up to 3, up to 2) amino acid conservative modifications compared to SEQ ID NO: 11. More preferably, the NKG2A antibody comprises a light chain variable region set forth in one selected from SEQ ID NOs: 10 and 13, and a heavy chain variable region set forth in SEQ ID NO: 11.

[0041] In one embodiment, the amino acid sequence of the NKG2A antibody is selected from SEQ ID NOs:12 and 14.

[0042] As used herein, the term "sequence identity" refers to the degree to which two (nucleotide or amino acid) sequences have the same residues at the same positions in a comparison, and is generally expressed as a percentage. Preferably, identity is determined over the entire length of the sequences being compared. Thus, two copies with the exact same sequence have 100% identity. Those skilled in the art recognize that sequence identity can be determined using several algorithms, such as Blast (Altschul et al. (1997) Nucleic Acids Res. 25:3389-3402), Blast2 (Altschul et al. (1990) J. Mol. Biol. 215:403-410), Smith-Waterman (Smith et al. (1981) J. Mol. Biol. 147:195-197) and ClustalW.

[0043] As used herein, the term "conservative modifications" refers to amino acid modifications that do not appreciably affect or alter the binding characteristics of an antibody or antibody fragment containing that amino acid sequence. These conservative modifications include amino acid substitutions, additions, and deletions. Modifications are introduced into the chimeric antigen receptor of the present invention by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. A conservative substitution of an amino acid is one in which an amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art and include basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, formadine thionine, tryptophan), β-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Conservative modifications may be selected based, for example, on similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or the amphipathic nature of such residues.

[0044] In one aspect, the present invention further provides a multispecific antibody (preferably a bispecific or trispecific antibody) comprising the NKG2A antibody described above and further comprising one or more second antibodies that specifically bind to other antigens.

[0045] As used herein, the term "multispecific" means that an antigen binding protein has polytopic specificity (i.e., is capable of specifically binding to two, three or more different epitopes on one biomolecule, or is capable of specifically binding to epitopes on two, three or more different biomolecules). As used herein, the term "bispecific" refers to an antigen binding protein having two different antigen binding specificities.

[0046] In one embodiment, the second antibody may have any antibody or antibody fragment format, such as, for example, a full length antibody, Fab, Fab', (Fab')2, Fv, scFv, scFv-scFv, microantibody, diabody or sdAb. Nucleic acids, vectors and host cells

[0047] In another aspect, the present invention relates to a nucleic acid molecule encoding an NKG2A antibody or a multispecific antibody of the present invention. The nucleic acid of the present invention may be RNA, DNA or cDNA. According to one embodiment of the present invention, the nucleic acid of the present invention is an essentially separate nucleic acid.

[0048] In one embodiment, the nucleic acid molecule encoding the NKG2A antibody has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a nucleotide sequence selected from SEQ ID NOs: 16 to 17, and the encoded NKG2A antibody is capable of specifically binding to NKG2A. Preferably, the nucleic acid molecule encoding the NKG2A antibody is set forth in SEQ ID NOs: 16 to 17.

[0049] The nucleic acid of the invention may be in the form of a vector, present in a vector and / or part of a vector, for example a plasmid, a sticky-end plasmid or a YAC. The vector is in particular an expression vector, i.e. a vector that allows the expression of the NKG2A antibody in vitro and / or in vivo (i.e. in a suitable host cell, host organism and / or expression system). The expression vector usually comprises at least one nucleic acid molecule of the invention, operably linked to one or more suitable expression control elements (e.g. promoters, enhancers, terminators, etc.). The selection of said control elements and their sequences for expression in a particular host is well within the skill of the art. Specific examples of control elements and other elements useful or necessary for the expression of the NKG2A antibody of the invention include, but are not limited to, promoters, enhancers, terminators, integrators, selection markers, leader sequences, reporter genes.

[0050] In another aspect, the present invention further provides a host cell expressing the NKG2A antibody, the multispecific antibody of the invention and / or comprising a nucleic acid or a vector of the invention. Preferred host cells of the invention are bacterial, fungal or mammalian cells.

[0051] Suitable bacterial cells include cells of gram-negative strains (e.g. Escherichia coli strains, Proteus strains, Pseudomonas strains), gram-positive bacterial strains (e.g. Bacillus strains, Streptomyces strains, Staphylococcus strains and Lactococcus strains).

[0052] Suitable fungal cells include cells of species of Trichoderma, Neurospora, and Aspergillus, or cells of species of Saccharomyces (e.g., Saccharomyces cerevisiae), Schizosaccharomyces (e.g., Schizosaccharomyces pombe), Pichia (e.g., Pichia pastoris and Pichia methanolophilus), and Hansenula.

[0053] Suitable mammalian cells include, for example, HEK293 cells, CHO cells, BHK cells, HeLa cells, COS cells, and the like.

[0054] However, the present invention may also be used with amphibian cells, insect cells, plant cells and any other cells known in the art for expressing heterologous proteins. Chimeric Receptors

[0055] In another aspect, the present invention further provides a chimeric receptor comprising the above-mentioned NKG2A antibody. Since NKG2A is an NK inhibitory receptor, the chimeric receptor comprising the NKG2A antibody can be used to suppress the killing activity of NK cells.

[0056] In one embodiment, the invention provides a chimeric receptor comprising one or more NK inhibitory ligands, a transmembrane domain and a signaling domain, wherein the NK inhibitory ligand comprises an NKG2A antibody as described above, or a multispecific antibody containing the NKG2A antibody, and the signaling domain comprises one or more costimulatory domains.

[0057] In one embodiment, the chimeric receptor comprises multiple types of NK inhibitory ligands, for example two types of NK inhibitory ligands, of which a first NK inhibitory ligand is the above-mentioned NKG2A antibody and a second NK inhibitory ligand is an antibody or a fragment thereof that targets another NK inhibitory receptor, and / or a natural ligand of the other NK inhibitory receptor or an NK inhibitory receptor binding region contained therein.

[0058] In one embodiment, the second NK inhibitory ligand is an NKG2 / CD94 component (e.g., NKG2B, CD94), a killer cell Ig-like receptor (KIR) family member (e.g., KIR2DL1, KIR2DL2 / 3, KIR2DL5A, KIR2DL5B, KIR3DL1, KIR3DL2 and KIR3DL3), a leukocyte Ig-like receptor (LIR) family member (e.g., LIR1, LIR2, LIR3, LIR5 and LIR8), an NK cell receptor protein 1 (NKR-P1) family member (e.g., NKR-P1B and NKR-P1D), and an immune checkpoint inhibitor. The second NK inhibitory ligand is an antibody or a fragment thereof that targets an NK inhibitory receptor selected from checkpoint receptors (e.g., PD-1, TIGIT, and CD96, TIM3, LAG3), carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), sialic acid-binding immunoglobulin-like lectin (SIGLEC) family members (e.g., SIGLEC7 and SIGLEC9), leukocyte-associated immunoglobulin-like receptor 1 (LAIR1), Ly49 family members (e.g., Ly49A, Ly49C, Ly49F, Ly49G1, and Ly49G4), and killer cell lectin-like receptor G1 (KLRG1). More preferably, the second NK inhibitory ligand is selected from an antibody or a fragment thereof that targets an NK inhibitory receptor such as NKG2B, CD94, LIR1, LIR2, LIR3, KIR2DL1, KIR2DL2 / 3, KIR3DL1, CEACAM1, LAIR1, and KLRG1. Even more preferably, said second NK inhibitory ligand is selected from an antibody or a fragment thereof that targets an NK inhibitory receptor such as CD94, KIR2DL1, KIR2DL2 / 3, KIR3DL1, CEACAM1, LIR1, LAIR1 and KLRG1.

[0059] In one embodiment, the second NK inhibitory ligand is a natural ligand of another NK inhibitory receptor or an NK inhibitory receptor binding region contained therein, such as HLA-E, HLA-F, HLA-G, cadherin, collagen, OCIL, sialic acid, immune checkpoint ligands (e.g., PD-L1 / PD-L2, CD155, CD112, CD113, Gal-9, FGL1, etc.), and an NK inhibitory receptor binding region contained therein. Preferably, the second NK inhibitory ligand is selected from HLA-E, HLA-F, HLA-G, cadherin, PD-L1, PD-L2, or an NK inhibitory receptor binding region contained therein. More preferably, the NK inhibitory ligand is selected from an HLA-E extracellular domain, an HLA-G extracellular domain, an E-cadherin extracellular domain, a PD-L1 extracellular domain, and a PD-L2 extracellular domain. More preferably, said second NK inhibitory ligand is the extracellular domain of E-cadherin and includes EC1 and EC2, more preferably EC1, EC2, EC3, EC4 and EC5.

[0060] As used herein, the term "transmembrane domain" refers to a polypeptide structure that allows the chimeric receptor to be expressed on the surface of an immune cell (e.g., lymphocyte, NK cell, or NKT cell) and guides the immune cell's cellular response to a target cell. The transmembrane domain may be natural or synthetic and may be derived from any membrane-bound or transmembrane protein. When the chimeric receptor and the target antigen are bound, the transmembrane domain is capable of signal transduction. It particularly applies to the transmembrane domain in the present invention and may be derived from, for example, the TCR alpha chain, the TCR beta chain, the TCR gamma chain, the TCR delta chain, the CD3 zeta subunit, the CD3 epsilon subunit, the CD3 gamma subunit, the CD3 delta subunit, CD45, CD4, CD5, CD8 alpha, CD9, CD16, CD22, CD33, CD28, CD37, CD64, CD80, CD86, CD134, CD137, CD154, and functional fragments thereof. Alternatively, the transmembrane domain may be synthetic and may comprise predominantly hydrophobic residues, such as leucine and valine. Preferably, said transmembrane domain is derived from the CD8 alpha chain or CD28 and has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 17 or 19, or has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity to the nucleic acid molecule whose coding sequence is shown in SEQ ID NO: 18 or 20.

[0061] As used herein, the term "costimulatory domain" refers to an intracellular functional signaling domain from a costimulatory molecule, including the entire intracellular portion of said costimulatory molecule, or a functional fragment thereof. A "costimulatory molecule" refers to a cognate binding gametophyte that specifically binds to a costimulatory ligand in T cells, thereby mediating a costimulatory response (e.g., proliferation) of T cells. Costimulatory molecules include, but are not limited to, MHC class 1 molecules, BTLA, and Toll ligand receptors. Non-limiting examples of costimulatory domains of the invention include, but are not limited to, intracellular regions derived from proteins such as TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, CARD11, CD2, CD7, CD8, CD18 (LFA-1), CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD134 (OX40), CD137 (4-1BB), CD270 (HVEM), CD272 (BTLA), CD276 (B7-H3), CD278 (ICOS), CD357 (GITR), DAP10, LAT, NKG2C, SLP76, PD-1, LIGHT, TRIM, and ZAP70. Preferably, the costimulatory domain of the CAR of the invention is derived from 4-1BB, CD28, or 4-1BB+CD28. In one embodiment, the 4-1BB costimulatory domain has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 23, or has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity to the nucleic acid molecule whose coding sequence is set forth in SEQ ID NO: 24. In one embodiment, the CD28 costimulatory domain has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 21, or has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity to the nucleic acid molecule whose coding sequence is set forth in SEQ ID NO: 22.

[0062] In one embodiment, the signaling domain is comprised of one or more costimulatory domains (i.e., does not include a primary signaling domain, such as, for example, a primary signaling domain from native FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b, and CD66d). In another embodiment, the signaling domain of a chimeric receptor of the invention may comprise a primary signaling domain, such as, for example, a CD3ζ intracellular domain. In a preferred embodiment, the CD3ζ intracellular domain has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 25 or 27, or has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity to a nucleic acid molecule whose coding sequence is set forth in SEQ ID NO: 26 or 28.

[0063] In one embodiment, the chimeric receptor of the invention may comprise a hinge region located between the antibody and the transmembrane domain. As used herein, the term "hinge region" generally refers to any oligopeptide or polypeptide that functions to link the transmembrane domain to the antibody. Specifically, the hinge region is intended to provide greater flexibility and accessibility to the antibody. The hinge region may comprise up to 300 amino acids, preferably 10-100 amino acids, and most preferably 25-50 amino acids. The hinge region may be derived in whole or in part from a naturally occurring molecule, for example, derived in whole or in part from the extracellular region of CD8, CD4 or CD28, or derived in whole or in part from an antibody constant region. Alternatively, the hinge region may be a synthetic sequence that corresponds to a naturally occurring hinge sequence, or may be a completely synthetic hinge sequence. In preferred embodiments, the hinge region comprises a portion of the hinge region of CD8α, CD28, an FcγRIIIα receptor, IgG4 or IgG1, more preferably a CD8α, CD28 or IgG4 hinge, and has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 33, 35 or 37, or the nucleotide sequence whose coding sequence has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity to the nucleotide sequence set forth in SEQ ID NO: 34, 36 or 38.

[0064] In one embodiment, the CR of the present invention may contain a signal peptide so that when expressed in a cell, e.g., a T cell, the nascent protein is introduced to the endoplasmic reticulum and then to the cell surface. The core of the signal peptide may contain a long hydrophobic amino acid segment and tends to form a single α-helix. At the end of the signal peptide, there is generally an amino acid segment that is recognized and cut by a signal peptidase. The signal peptidase is cut during translocation or after completion to generate a free signal peptide and a mature protein. The free signal peptide is then digested by a specific protease. Signal peptides applicable to the present invention are well known by those skilled in the art, for example, signal peptides derived from B2M, CD8α, IgG1, GM-CSFRα, etc. In one embodiment, the signal peptide applicable to the present invention is derived from B2M or CD8α and has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 29 or 31, or its coding sequence has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity to the nucleic acid molecule set forth in SEQ ID NO: 30 or 32.

[0065] In one embodiment, the CR comprises an NKG2A antibody provided herein, or a multispecific antibody containing the NKG2A antibody, a CD8α transmembrane domain and a signaling domain, wherein the signaling domain comprises a costimulatory domain selected from CD28 and 4-1BB. Preferably, the signaling domain is comprised of a costimulatory domain selected from CD28 and 4-1BB. In another embodiment, the signaling domain further comprises a CD3ζ intracellular domain. In this embodiment, the CAR may further comprise a signal peptide derived from B2M, CD8α, IgG1, or GM-CSFRα.

[0066] The present invention further provides a nucleic acid molecule encoding a chimeric receptor targeting NKG2A as defined above, and a vector comprising said nucleic acid molecule.

[0067] As used herein, the term "vector" refers to a mediator nucleic acid molecule for the transfer of (exogenous) genetic material into a host cell, where said nucleic acid molecule may, for example, be copied and / or expressed. Vectors generally include targeting vectors and expression vectors. A "targeting vector" is a vehicle that delivers isolated nucleic acids to the interior of a cell, for example by homologous recombination or by using a hybrid recombinase of sequences at a specific target site. An "expression vector" is a vector that is used for the transcription of heterologous nucleic acid sequences (e.g., those sequences encoding the chimeric receptor peptide of the present invention) in a compatible host cell and the translation of their mRNA. Suitable vectors applicable to the present invention are known in the art and can be obtained commercially in large quantities. In one embodiment, vectors of the invention include, but are not limited to, plasmids, viruses (e.g., retroviruses, lentiviruses, adenoviruses, vaccinia viruses, Rous sarcoma viruses (RSV, polyomaviruses, and adeno-associated viruses (AAV)), phages, phagemids, cosmids, and artificial chromosomes (including BACs and YACs). The vector itself is generally a nucleic acid molecule, generally a DNA sequence that contains an insert (gene transfer) and a larger sequence that is the "skeleton" of the vector. Modified vectors also generally contain an origin of autonomous replication in a host cell (if necessary for stable expression of the polynucleotide), a selection marker, and restriction enzyme cleavage sites (e.g., a multiple cloning site, MCS). Vectors may further include elements such as a promoter, a polyA tail (polyA), a 3'UTR, an enhancer, a terminator, an insulator, an operator, a selection marker, a reporter gene, a targeting sequence, and / or a protein purification tag. In a specific embodiment, the vector is an in vitro transcription vector. Engineered immune cells

[0068] NKG2A can be bound to non-classical HLA class I molecules such as HLA-E, and further inhibit the activation of immune cells, such as NK cells. Therefore, exogenous NKG2A antibodies can achieve the effect of inhibiting the killing activity of NK cells by binding to NKG2A, which is particularly useful in some cases (e.g., when HLA class I molecules are deleted or when preparing universal CAR-T cells).

[0069] Thus, in one aspect, the invention further provides a modified immune cell that expresses a chimeric receptor comprising an NKG2A antibody of the invention, in which expression of at least one MHC-associated gene is suppressed or silenced. In a preferred embodiment, the modified immune cell further expresses a second chimeric receptor comprising a second NK inhibitory ligand, in which the second NK inhibitory ligand is an antibody or a fragment thereof that targets another NK inhibitory receptor and / or a natural ligand of the other NK inhibitory receptor or an NK inhibitory receptor-binding domain contained therein.

[0070] As used herein, MHC-associated genes include MHC genes themselves (e.g., MHC class I molecules and MHC class II molecules) and genes that interact with or modulate the expression of MHC genes. Examples of MHC class I molecules include, but are not limited to, HLA-A, HLA-B, HLA-C, B2M. Examples of MHC class II molecules include, but are not limited to, HLA-DPA1, HLA-DQA1, and HLA-DRA. Examples of genes that interact with or modulate the expression of MHC genes include, but are not limited to, TAP1, TAP2, LMP2, LMP7, RFX5, RFXAP, RFXANK, and CIITA.

[0071] Thus, in one embodiment, suppressing or silencing the expression of an MHC-related gene means suppressing or silencing the expression of one or more genes selected from HLA-A, HLA-B, HLA-C, B2M, HLA-DPA, HLA-DQ, HLA-DRA, TAP1, TAP2, LMP2, LMP7, RFX5, RFXAP, RFXANK, CIITA, and combinations thereof, preferably selected from HLA-A, HLA-B, HLA-C, B2M, RFX5, RFXAP, RFXANK, CIITA, and combinations thereof.

[0072] In one embodiment, the modified immune cells expressing a chimeric receptor comprising an NKG2A antibody of the present invention further comprise at least one TCR / CD3 gene, the expression of which is inhibited or silenced, examples of which include, for example, TRAC, TRBC, CD3γ, CD3δ, CD3ε, CD3ζ.

[0073] In a preferred embodiment, the modified immune cell expressing a chimeric receptor of the present invention comprises at least one TCR / CD3 gene and at least one MHC associated gene, the expression of which is inhibited or silenced, wherein the at least one TCR / CD3 gene is selected from TRAC, TRBC, CD3γ, CD3δ, CD3ε, CD3ζ and combinations thereof, and the at least one MHC associated gene is selected from HLA-A, HLA-B, HLA-C, B2M, HLA-DPA, HLA-DQ, HLA-DRA, TAP1, TAP2, LMP2, LMP7, RFX5, RFXAP, RFXANK, CIITA and combinations thereof, preferably HLA-A, HLA-B, HLA-C, B2M, RFX5, RFXAP, RFXANK, CIITA and combinations thereof.

[0074] In a preferred embodiment, the at least one TCR / CD3 gene is selected from TRAC, TRBC, and a combination thereof, and the at least one MHC-related gene is selected from B2M, RFX5, RFXAP, RFXANK, CIITA, and a combination thereof. In an embodiment, the expression of TRAC or TRBC, and B2M in the modified immune cell is suppressed or silenced. In an embodiment, the expression of TRAC or TRBC, and CIITA in the modified immune cell is suppressed or silenced. In a preferred embodiment, the expression of TRAC or TRBC, B2M, and CIITA in the modified immune cell is suppressed or silenced. In a preferred embodiment, the expression of TRAC or TRBC, B2M, and RFX5 in the modified immune cell is suppressed or silenced.

[0075] Methods of suppressing gene expression or silencing genes are well known to those of skill in the art and include, but are not limited to, mediating DNA cleavage with meganucleases, zinc finger nucleases, TALE nucleases, or Cas enzymes of the CRISPR system, or inactivating genes with techniques such as antisense oligonucleotides, RNAi, shRNA, etc.

[0076] In one embodiment, the modified immune cells provided herein further express a chimeric antigen receptor that targets a tumor antigen.

[0077] In one embodiment, the chimeric antigen receptor is TSHR, CD19, CD123, CD22, CD30, CD171, CS-1, CLL-1, CD33, EGFRvIII, GD2, GD3, BCMA, Tn Ag, PSMA, ROR1, FLT3, FAP, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, mesothelin, IL-1 lRa, PSCA, PRSS21, VEGFR2, LewisY, CD24, PDGFR-β, SSEA-4, CD20, Folate receptor alpha, ERBB2 (Her2 / neu), MUC1, EGFR, NCAM, Prostase, PAP, ELF2M, Ephrin B2, IGF-I receptor, CAIX, LMP2, gploo, bcr-abl, tyrosinase, EphA2, Fucosyl GMl, sLe, GM3, TGS5, HMWMAA, o-acetyl-GD2, Folate receptor beta, TEM1 / CD248, TEM7R, CLDN6, GPRC5D, CXORF61, CD97, CD 179a, ALK, polysialic acid, PLAC1, GloboH, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, GPR20, LY6K, OR51E2, TARP, WT1, NY-ESO-1, LAGE-la, MAGE-A1, pod protein, HPV E6, E7, MAGE Al, ETV6-AML, sperm protein 17, XAGE1, Tie 2, MAD-CT-1, MAD-CT-2, Fos-related antigen 1, p53, p53 mutant, prostate-specific protein, survivin and telomerase, PCTA-l / Galectin 8, MelanA / MARTl, Ras mutant, hTERT, sarcoma translocation breakpoint, ML-IAP, ERG (TMPRSS2ETS fusion gene), NA17, PAX3, androgen receptor, Cyclin Bl, MYCN, RhoC, TRP-2, CYP1B1, BORIS, SART3, PAX5, OY-TES 1, LCK, AKAP-4, SSX2, RAGE-1, human telomerase reverse transcriptase, RU1, RU2, intestinal carboxylesterase, mutThe targeting of the tumor antigen is selected from hsp70-2, CD79a, CD79b, CD72, LAIR1, FCAR, LILRA2, CD300LF, CLEC12A, BST2, EMR2, LY75, GPC3, FCRL5, IGLL1, PD1, PDL1, PDL2, TGFβ, APRIL, NKG2D, and any combination thereof. Preferably, the target is selected from CD19, CD20, CD22, BAFF-R, CD33, EGFRvIII, BCMA, GPRC5D, PSMA, ROR1, FAP, ERBB2 (Her2 / neu), MUC1, EGFR, CAIX, WT1, NY-ESO-1, CD79a, CD79b, GPC3, Claudin18.2, NKG2D, and any combination thereof. Depending on the antigen to be targeted, the chimeric antigen receptor of the present invention may be designed to include an antibody with specificity for this antigen. For example, if CD19 is the targeted antigen, then a CD19 antibody can be used in the chimeric antigen receptor of the present invention.

[0078] As used herein, the term "immune cell" refers to any cell of the immune system that has one or more effector functions (e.g., killing activity of cytotoxic cells, secretion of cytokines, induction of ADCC and / or CDC). For example, the immune cell is a T cell, a macrophage, a dendritic cell, a monocyte, a NK cell and / or a NKT cell. In one embodiment, the immune cell is derived from a stem cell, such as an adult stem cell, an embryonic stem cell, an umbilical cord blood stem cell, a progenitor cell, a bone marrow stem cell, an induced pluripotent stem cell, a totipotent stem cell, or a hematopoietic stem cell. Preferably, the immune cell is a T cell. The T cell may be any T cell, such as an ex vivo cultured T cell, such as a primitive T cell, or from an in vitro cultured T cell line, such as a T cell, such as Jurkat, SupT1, etc., or a T cell obtained from a subject. Examples of subjects include humans, dogs, cats, mice, rats, and transgenic species thereof. T cells can be obtained from multiple sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue from an infection site, ascites, pleural effusion, spleen tissue, and tumors. T cells may be enriched or purified. T cells may be at any stage of development, including, but not limited to, CD4+ / CD8+ T cells, CD4+ helper T cells (e.g., Th1 and Th2 cells), CD8+ T cells (e.g., cytotoxic T cells), tumor infiltrating cells, memory T cells, naive T cells, γδ-T cells, αβ-T cells, and the like. In a preferred embodiment, the immune cells are human T cells. T cells can be obtained from the blood of a subject using a variety of techniques known to those skilled in the art, such as Ficoll separation.

[0079] Common methods known in the art (e.g., transduction, transfection, transformation, etc.) can be employed to introduce the nucleic acid sequence encoding the chimeric receptor into immune cells. "Transfection" is the process of introducing a nucleic acid molecule or polynucleotide (including a vector) into a target cell. One example is RNA transfection, i.e., the process of introducing RNA (e.g., in vitro transcribed RNA, ivtRNA) into a host cell. This term is primarily used for non-viral approaches in eukaryotic cells. The term "transduction" is generally used to describe virus-mediated transfer of a nucleic acid molecule or polynucleotide. Transfection of animal cells generally involves the temporary opening of pores or "holes" in the cell membrane to allow uptake of the material. Transfection can be achieved using calcium phosphate, electroporation, cell extrusion, and by mixing cationic lipids with materials to generate lipid bodies that fuse to the cell membrane and deposit their carriers inside. Exemplary techniques used for transfection of eukaryotic host cells include lipid vesicle-mediated uptake, heat shock-mediated uptake, calcium phosphate-mediated transfection (calcium phosphate / DNA co-precipitation), microinjection and electroporation. The term "transformation" is intended to describe the transfer of nucleic acid molecules or polynucleotides (including vectors) into bacteria, non-viral, non-animal eukaryotic cells (including plant cells). Thus, transformation is the genetic modification of bacteria or non-animal eukaryotic cells, which is produced by direct uptake from its surroundings by the cell membrane and then incorporating exogenous genetic material (nucleic acid molecules). Transformation may also be achieved by artificial means. For transformation to occur, the cell or bacteria must be in a competent state. For prokaryotic transformation, techniques include heat shock-mediated uptake, fusion of whole cells with bacterial protoplasts, microinjection and electroporation. Once the nucleic acid or vector has been introduced into immune cells, the skilled artisan can amplify and activate the obtained immune cells by common techniques.

[0080] In one embodiment, the present invention further provides multiple types of engineered immune cells, where one type of immune cell expresses the chimeric receptor described in the present invention and any chimeric antigen receptor that targets a tumor antigen, and the other type of immune cell expresses a second chimeric receptor that targets another NK inhibitory receptor. In this embodiment, the second chimeric receptor comprises a second NK inhibitory ligand, a transmembrane domain, and a signaling domain, the definitions of the second NK inhibitory ligand, the transmembrane domain, and the signaling domain are described in the "Chimeric Receptor" section. In such an embodiment, the multiple types of engineered immune cells may be administered together or separately. In one embodiment, the multiple types of immune cells may be in the same composition or in different compositions. Exemplary compositions of cells include the compositions described in the following sections of this application. antibody complex

[0081] In another aspect, the invention provides an antibody conjugate comprising an NKG2A antibody as defined in the invention and a second functional structure, wherein said second functional structure is selected from an Fc, a radioisotope, a structural moiety that extends half-life, a detectable marker and a drug.

[0082] In one embodiment, the present invention provides an antibody complex comprising an NKG2A antibody as defined herein and an Fc. As used herein, the term "Fc" is intended to define the C-terminal region of an immunoglobulin heavy chain and includes native Fc and variant Fc. "Native Fc" refers to a molecule or sequence that is generated by digestion of an intact antibody and includes a non-antigen binding fragment that may be in the form of a monomer or polymer. The source of immunoglobulin from which the native Fc is generated is preferably of human origin. A native Fc fragment may be composed of monomeric polypeptides that are linked as a dimer or polymer by covalent (e.g., disulfide bonds) and non-covalent bonds. Depending on the category (e.g., IgG, IgA, IgE, IgD, IgM) or subtype (e.g., IgG1, IgG2, IgG3, IgA1, IgGA2), there are 1-4 intermolecular disulfide bonds between monomeric subunits of the native Fc molecule. As an example of a native Fc, papain is used to digest disulfide-bonded dimers generated from IgG (see Ellison et al. (1982), Nucleic Acids Res. 10:4071-9). As used herein, "native Fc" generally refers to monomeric, dimeric and polymeric forms. "Variant Fc" refers to an amino acid sequence that differs from that of a "native" or "wild-type" Fc by at least one document-defined "amino acid modification", also referred to as an "Fc variant". Thus, "Fc" also includes single-chain Fc (scFc), i.e., a single-chain Fc consisting of two Fc monomers linked by a polypeptide linker, capable of naturally folding into a functional dimeric Fc region. In one embodiment, the Fc is preferably a human immunoglobulin Fc, more preferably a human IgG1 Fc.

[0083] In one embodiment, the present invention provides an antibody conjugate comprising an NKG2A antibody as defined in the present invention and a radioisotope. 211 , I 131 , I 125 , Y 90 , Re186 , Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 , 99m Tc, 123 I, 18 F and 68 Including, but not limited to, Ga.

[0084] In one embodiment, the invention provides an antibody conjugate comprising an NKG2A antibody as defined in the invention and a half-life extending structural moiety, wherein said half-life extending structural moiety is selected from an albumin binding structure, a transferrin binding structure, a polyethylene glycol molecule, a recombinant polyethylene glycol molecule, human serum albumin, a fragment of human serum albumin and a white polypeptide (including an antibody) bound to human serum albumin.

[0085] In one embodiment, the present invention provides an antibody complex comprising an NKG2A antibody as defined in the present invention and a detectable marker. The term "detectable marker" refers herein to a compound that generates a detectable signal. For example, a detectable marker may be an MRI contrast agent, a scintigraphy contrast agent, an X-ray imaging contrast agent, an ultrasound imaging contrast agent, an optical imaging contrast agent. Examples of detectable markers include fluorophores (e.g., fluorescein, Alexa, or cyanine), chemiluminescent compounds (e.g., luminol), bioluminescent compounds (e.g., luciferase or alkaline phosphatase), enzymes (e.g., horseradish peroxidase, glucose-6-phosphatase, β-galactosidase), antibiotics (e.g., kanamycin, ampicillin, chloramphenicol, tetracycline, etc.), resistance genes, and contrast agents (e.g., nanoparticles or gadolinium). The skilled artisan can select an appropriate detectable marker based on the detection system used.

[0086] In one embodiment, the invention provides an antibody conjugate comprising an NKG2A antibody as defined in the invention and an agent, such as a cytotoxin or an immunomodulatory agent (i.e., an antibody-drug conjugate), attached to said NKG2A antibody. Typically, the agent is covalently attached to the antibody and generally depends on a linker. In one embodiment, the agent is a cytotoxin. In another embodiment, the agent is an immunomodulatory agent. Examples of cytotoxins include methotrexate, aminopterin, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil, dacarbazine, nitrogen mustard, thiotepa, chlorambucil, melphalan, carmustine (BSNU), lomustine (CCNU), 1-methylnitrosourea, cyclophosphamide, nitrogen mustard, busulfan, dibromomannitol, streptozocin, mitomycin, cis-dichlorodiammineplatinum(II) (DDP), cisplatin, carboplatin, zorubicin, doxorubicin, detorubicin, caminomycin, idarubicin, epirubicin, mitoxantrone, actinomycin D, bleomycin, bromobutane ... In some embodiments, the therapeutic agent may be an antineoplastic agent, such as, but not limited to, mycin, calicheamicin, mithromycin, anthramycin (AMC), vincristine, vinblastine, paclitaxel, ricin, pseudomonas exotoxin, gemcitabine, cytochalasin B, gramicidin D, ethidium bromide, emetine, etoposide, teniposide, colchicine, dihydroxyanthracenedione, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, procarbazine, hydroxycarbamide, asparaginase, corticosteroids, mitotane (O,P'-(DDD)), interferon, and combinations thereof.Examples of immunomodulatory agents include, but are not limited to, ganciclovir, etanercept, tacrolimus, sirolimus, voclosporin, cyclosporin, rapamycin, cyclophosphamide, azathioprine, mycophenolate mofetil, methotrexate, glucocorticoids and their analogs, cytokines, stem cell growth factors, lymphotoxins, tumor necrosis factors (TNF), hematopoietic factors, interleukins (e.g., IL-1, IL-2, IL-3, IL-6, IL-10, IL-12, IL-18, and IL-21), colony stimulating factors (e.g., G-CSF and (GM-CSF), interferons (e.g., interferon-α, interferon-β, and interferon-γ), stem cell growth factors designated as "S1 factors," erythropoietin, and thrombopoietin, or combinations thereof. Kits and pharmaceutical compositions

[0087] In another aspect, the present invention further provides a detection kit comprising an antibody, a multispecific antibody, a chimeric receptor or an antibody complex according to the present invention.

[0088] In another aspect, the present invention further provides a pharmaceutical composition comprising an antibody, chimeric receptor, multispecific antibody or antibody complex according to the invention, and one or more pharma- ceutically acceptable excipients.

[0089] As used herein, the term "pharmaceutical acceptable excipient" refers to a vector and / or excipient that is pharmacologically and / or physiologically compatible with the subject and the active ingredient (i.e., achieves the desired therapeutic effect without exerting any undesired local or systemic effects) and is well known in the art (see, e.g., Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995). Examples of pharmaceutical acceptable excipients include, but are not limited to, fillers, binders, disintegrants, coating agents, adsorbents, anti-adherents, glidants, antioxidants, flavorings, coloring agents, sweeteners, solvents, cosolvents, buffers, chelating agents, surfactants, diluents, wetting agents, preservatives, emulsifiers, coating agents, isotonicity agents, absorption retardants, stabilizers, and isotonicity agents. Those skilled in the art will know how to select the appropriate excipients to prepare the desired pharmaceutical composition of the present invention. Exemplary excipients in pharmaceutical compositions for use in the present invention are saline, buffered saline, dextrose, and water. The selection of a suitable excipient generally depends on the particular active agent used, the disease to be treated, and the desired form of the pharmaceutical composition.

[0090] The pharmaceutical compositions of the present invention may be administered by several routes. Generally, administration is accomplished parenterally. Parenteral administration methods include topical, intraarterial, intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, intrauterine, intravaginal, sublingual, or intranasal administration.

[0091] The pharmaceutical compositions of the present invention can be prepared in various forms, such as solid, liquid, gaseous, lyophilized forms, in particular in the form of ointments, creams, transdermal patches, gels, powders, tablets, solutions, aerosols, granules, pills, suspensions, emulsions, capsules, syrups, elixirs, extracts, tinctures, liquid extracts, or in a form that is particularly adapted to the required method of administration. The process of producing the drugs known in the present invention may include, for example, routine mixing, dissolving, granulating, dragee-making, milling, emulsifying, encapsulating, encapsulating, or lyophilizing processes. For example, the pharmaceutical compositions comprising immune cells described herein are generally provided in the form of a solution, and preferably include a pharma- ceutical acceptable buffer.

[0092] The pharmaceutical composition according to the invention can also be administered in combination with one or more other drugs applied in the treatment and / or prevention of the disease to be treated. Preferred examples of drugs applied in combination are e.g. cisplatin, maytansine derivatives, rachelmycin, calicheamicin, docetaxel, etoposide, gemcitabine, ifosfamide, irinotecan, melphalan, mitoxantrone, sorfimer sodium photofrin II, temozolomide, topotecan, trimetrexate glucuronate, auristatin E, and cisplatin. E), known anti-cancer drugs such as vincristine and adriamycin, peptide cytotoxins such as ricin, diphtheria toxin, Pseudomonas exotoxin A, DNA enzymes and RNA enzymes, radionuclides such as iodine-131, rhenium-186, indium-111, iridium-90, bismuth-210 and 213, actinium-225 and astatine-213, prodrugs of antibody-directed enzyme prodrugs, immunostimulants such as platelet factor 4, melanoma growth stimulating protein, antibodies or fragments thereof such as anti-CD3 antibodies or fragments thereof, complement activators, heteroprotein domains, homoprotein domains, viral / bacterial protein domains, and viral / bacterial peptides. The pharmaceutical compositions of the present invention may also be used in combination with one or more other therapeutic methods, such as chemotherapy, radiotherapy, etc. Therapeutic, preventive and diagnostic uses

[0093] In another aspect, the present invention further provides a method for treating, preventing or diagnosing a disease associated with NKG2A expression, comprising administering to a subject the above-mentioned antibody, multispecific antibody, antibody conjugate, or pharmaceutical composition.

[0094] In one embodiment, diseases associated with NKG2A expression include cancer, infectious diseases, inflammatory diseases, and autoimmune diseases. Examples of cancers treatable with the antibodies of the present invention include solid cancers, including bladder cancer, breast cancer, colon cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, pancreatic cancer, gastric cancer, cervical cancer, thyroid cancer, and skin cancer, including squamous cell carcinoma; hematopoietic lymphomas, including leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma, Burkitt's lymphoma, and multiple myeloma; and acute and chronic myelogenous lymphomas. Myeloid hematopoietic tumors including leukemia, promyelocytic leukemia, myelodysplastic syndromes; mesenchymal derived tumors including fibrosarcoma and rhabdomyosarcoma; other tumors including melanoma, seminoma, teratocarcinoma, neuroblastoma, and glioma; central and peripheral nervous system tumors including astrocytoma, neuroblastoma, glioma, schwannoma; mesenchymal derived tumors including fibrosarcoma, rhabdomyosarcoma, osteosarcoma; other tumors including melanoma, xeroderma pigmentosum, keratoacanthoma, seminoma, thyroid follicular carcinoma, teratocarcinoma. Examples of infectious diseases treatable with the antibodies of the invention include, but are not limited to, infections caused by viruses, bacteria, protozoa, or fungi, such as viruses including, for example, hepatitis A virus, hepatitis B virus, hepatitis C virus, influenza virus, chickenpox virus, adenovirus, herpes simplex type 1 (HSV-1), herpes simplex type 2 (HSV-2), rinderpest, rhinovirus, ecovirus, rotavirus, respiratory syncytial virus, papillomavirus, cytomegalovirus, arbovirus, coxsackievirus, mumps virus, measles virus, rubella virus, poliovirus, human immunodeficiency virus type 1 or 2 (HIV-1, HIV-2), and bacteria including, for example, staphylococci, streptococci, bacilli, lactic acid bacteria, listeria, diphtheria corynebacterium, and the like.Examples of inflammatory diseases treatable with the antibodies of the invention include, but are not limited to, adrenalitis, alveolitis, cholecystitis, appendicitis, balanoposthitis, blepharitis, bronchitis, bursitis, carditis, cellulitis, cervicitis, cholecystitis, vocal cord inflammation, cochleitis, colitis, conjunctivitis, cystitis, dermatitis, diverticulitis, encephalitis, endocarditis, esophagitis, eustachian tube inflammation, fibrous tissue inflammation, folliculitis, gastritis, gastroenteritis, gingivitis, glossitis, hepatosplenitis, keratitis, laryngitis, lymphangitis, mastitis, otitis media, meningitis, metritis, mucositis, and the like. Examples of autoimmune diseases treatable with the antibodies of the invention include, but are not limited to, hemolytic anemia, pernicious anemia, polyarteritis nodosa, systemic lupus erythematosus, Wegener's granulomatosis, autoimmune hepatitis, Behcet's disease, Crohn's disease, primary biliary cirrhosis, scleroderma, ulcerative colitis, Sjogren's syndrome, type 1 diabetes, uveitis, Graves' disease, Alzheimer's disease, psoriasis, vitiligo, and the like.

[0095] In another embodiment, when the chimeric receptor comprising the anti-NKG2A antibody of the present invention is co-expressed in immune cells with a chimeric antigen receptor targeting a tumor antigen, the treatable disease is determined by the tumor antigen targeted by the chimeric antigen receptor. For example, when the chimeric receptor comprising the anti-NKG2A antibody of the present invention is co-expressed or administered with a chimeric antigen receptor targeting CD19, the treatable disease is a disease related to CD19 expression, such as B-cell malignancies including acute lymphoblastic leukemia (B-ALL), B-chronic lymphocytic leukemia (B-CLL), B-cell Hodgkin's lymphoma (B-HL) and non-Hodgkin's lymphoma (B-NHL), etc. In this embodiment, the chimeric receptor comprising the anti-NKG2A antibody is for suppressing the killing of reinfused modified immune cells by NK cells, while the chimeric antigen receptor targets and kills the target cells by binding to the tumor antigen.

[0096] The present invention will be described in detail below with reference to the drawings and examples. It should be noted that those skilled in the art should understand that the drawings and the embodiments of the present invention are merely illustrative and do not constitute any limitations on the present invention. If not inconsistent, the features in the embodiments and the embodiments in this application can be combined with each other. [Brief description of the drawings]

[0097] [Figure 1] 1 shows a comparison of the sequences of the light and heavy chain variable regions of hZ199 and its back-mutated antibodies hZ199-V1 and hZ199-V2. The amino acid sites of the back-mutations are highlighted in grey, and the numbers indicate the positions of the mutation sites in the light and heavy chain variable regions. [Diagram 2] 1 shows the scFv expression levels of UNKi-T cells containing the NKG2A antibody. [Diagram 3] The inhibitory effect of UNKi-T cells containing NKG2A antibody on NK cell killing is shown. Analyzed by Two-way ANOVA and statistically analyzed by Ttest. ** indicates that the P value is less than 0.01 and reaches a significant level. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0098] Example 1. Preparation of NKG2A antibodies In order to enhance the affinity and specificity of the antibody, a new NKG2A antibody is prepared by back mutation based on humanized Z199 antibody (hZ199). hZ199 includes CDR-L1 shown in SEQ ID NO:1, CDR-L2 shown in SEQ ID NO:2, CDR-L3 shown in SEQ ID NO:3, CDR-H1 shown in SEQ ID NO:4, CDR-H2 shown in SEQ ID NO:5, and CDR-H3 shown in SEQ ID NO:6, and the amino acid sequence of its light chain variable region is shown in SEQ ID NO:7, the amino acid sequence of its heavy chain variable region is shown in SEQ ID NO:8, and the full-length amino acid sequence is shown in SEQ ID NO:9. Methods for backmutation are known in the art. For example, backmutation primers are designed for some amino acids (mainly framework regions) in the hZ199 sequence that may affect antibody affinity, five mutation sites are designed in the light chain variable region, and four mutation sites are designed in the heavy chain variable region, and finally combined to obtain two backmutated antibodies, named hZ199-V1 and hZ199-V2, whose sequences are shown in Table 1 below.

[0099] Table 1. Sequences of hZ199 and its back mutant antibodies JPEG0007590034000001.jpg64170Example 2. Preparation of UNKi-T cells expressing chimeric receptors containing NKG2A antibodies and verification of their functions

[0100] Sequences encoding proteins such as B2m signal peptide (sequence number 29), hZ199 (sequence number 9) or hZ199-V1 (sequence number 12), CD28 hinge (sequence number 35), CD8α transmembrane region (sequence number 17), and CD28 costimulatory domain (sequence number 21) are synthesized and cloned into a pLVX vector (Public Protein / Plasmid Library (PPL), product number: PPL00157-4a) to obtain hZ199 plasmid and hZ199-V1 plasmid, and the correct insertion of the target sequence into the plasmid is confirmed by sequencing.

[0101] Sequences encoding proteins such as CD8α signal peptide (sequence number 31), hZ199-V2 (sequence number 14), IgG4 hinge (sequence number 37), CD28 transmembrane region (sequence number 19), and 4-1BB costimulatory domain (sequence number 23) are synthesized and cloned into a pLVX vector (Public Protein / Plasmid Library (PPL), product number: PPL00157-4a) to obtain the hZ199-V2 plasmid, and the correct insertion of the target sequence in the plasmid is confirmed by sequencing.

[0102] Add 3ml of Opti-MEM (Gibco, product number 31985-070) to a sterile tube to dilute the above plasmid, then add the packaging vector psPAX2 (Addgene, product number 12260) and envelope vector pMD2.G (Addgene, product number 12259) in a ratio of plasmid:viral packaging vector:viral envelope vector = 4:2:1. Then add 120ul of X-treme GENE HP DNA transfection reagent (Roche, product number 06366236001), mix evenly immediately, incubate at room temperature for 15 minutes, and then add the plasmid / vector / transfection reagent mixture drop by drop into the culture flask of 293T cells. After 24 hours and 48 hours, collect the virus, combine it, and then ultracentrifuge (25000g, 4℃, 2.5 hours) to obtain concentrated lentivirus.

[0103] T cells were activated using DynaBeads CD3 / CD28 CTS™ (Gibco, product number 40203D) and cultured for 1 day at 37°C and 5% CO2, and then the concentrated lentivirus was added. After 3 days of continuous culture, T cells expressing the chimeric receptor containing the NKG2A antibody were obtained.

[0104] Then, using the CRISPR / Cas9 system, the TCR / CD3 components (specifically, the TRAC gene) and MHC-related genes (specifically, B2M and RFX5) in wild-type T cells (i.e., NT cells) and the T cells expressing a chimeric receptor containing the NKG2A antibody are knocked out to obtain Mock T cells, UNKi-hZ99-T cells (containing the hZ199 plasmid), UNKi-V1-T cells (containing the hZ199-V1 plasmid), and UNKi-V2-T cells (containing the hZ199-V2 plasmid), respectively. The expression efficiency of CD3 / HLA-I / HLA-II in UNKi-T cells, Mock T cells and NT cells was detected by flow cytometry using FITC Mouse Anti-Human CD3 (BD ​​Pharmingen, product number 555916) antibody, PE mouse anti-human HLA-I (R&D product number FAB7098P) and APC anti-human DR, DP, DQ (biolegend, product number 361714) antibody, and the results are shown in Table 2 below.

[0105] Table 2. Gene expression efficiency in UNKi-T cells JPEG0007590034000002.jpg70170

[0106] As can be seen from Table 2, the expression of CD3 / HLA-I / HLA-II in UNKi-T cells and Mock T cells prepared in the present invention is efficiently suppressed or silenced.

[0107] Anti-NKG2A scFv expression in UNKi-T cells and Mock T cells was detected using Biotin-SP (long spacer) AffiniPure Goat Anti-Human IgG, F(ab')fragment specific antibody (Jackson ImmunoResearch, product number 109-065-097) and APC Streptavidin (BD, product number 554067) (Figure 2).

[0108] As can be seen from this, all of the scFvs in the UNKi-T cells prepared in the present invention are efficiently expressed.

[0109] The inhibitory effect of the UNKi-T cells prepared in the present invention on the killing activity of NK cells was detected by the following method, that is, Far-Red (Invitrogen, Product No. C34564) was used to mark the UNKi-T cells prepared in the present invention and Mock-T cells. 4 Marked UNKi-T cells and MockT cells were placed in a 96-well plate at a concentration of 100 cells / well, and NK92 cells were added at an effector:target ratio of 2:1 to perform co-culture. After 16-18 hours, the ratio of T cells in the culture was detected using flow cytometry, and the killing effect of NK cells on T cells was further calculated. The results are shown in Figure 3.

[0110] As can be seen from Figure 3, compared to NT cells that do not express a chimeric receptor, the UNKi-T cells of the present invention can significantly reduce the killing action of NK cells against T cells. In addition, compared to the hZ199 antibody, the use of the antibodies of the present invention (i.e., the back mutant hZ199-V1 and hZ199-V2 antibodies) shows a better inhibitory effect on the killing action of NK cells, and the affinity of the antibodies of the present invention is greater than that of the hZ199 antibody.

[0111] It should be explained that the above is only a preferred embodiment of the present invention, and does not limit the present invention, and the present invention can be modified and changed by those skilled in the art. As understood by those skilled in the art, any modifications, equivalent replacements, improvements, etc. made in accordance with the spirit and principle of the present invention should be included within the protection scope of the present invention.

Claims

1. An antibody targeting NKG2A, comprising a light chain variable region and a heavy chain variable region, The light chain variable region is represented by SEQ ID NO: 10 or 13, and the heavy chain variable region is represented by SEQ ID NO:

11. An antibody targeting NKG2A, characterized in that:

2. The amino acid sequence is represented by SEQ ID NO: 12 or 14. An antibody targeting NKG2A, characterized in that:

3. A nucleic acid molecule encoding the antibody of claim 1 or 2.

4. A multispecific antibody comprising the antibody of claim 1 or 2 and one or more second antibodies or antigen-binding portions thereof that specifically bind to other antigens.

5. The second antibody or antigen-binding portion thereof may be a full length antibody, a Fab, a Fab', a (Fab') 2 5. The multispecific antibody of claim 4, selected from the group consisting of Fv, scFv, scFv-scFv, microantibody, diabody and sdAb.

6. 6. A vector comprising a nucleic acid molecule encoding an antibody according to claim 1 or 2, or a multispecific antibody according to claim 4 or 5.

7. A host cell expressing an antibody according to claim 1 or 2, or a multispecific antibody according to claim 4 or 5.

8. A chimeric receptor comprising one or more NK inhibitory ligands, a transmembrane domain and a signaling domain, wherein the NK inhibitory ligand comprises an antibody of claim 1 or 2, or a multispecific antibody of claim 4 or 5, and the signaling domain comprises one or more costimulatory domains.

9. The chimeric receptor of claim 8, comprising two types of NK inhibitory ligands, wherein the first NK inhibitory ligand comprises the antibody of claim 1 or 2 or the multispecific antibody of claim 4 or 5, and the second NK inhibitory ligand is selected from (1) an antibody or fragment thereof targeting an NK inhibitory receptor such as NKG2A, NKG2B, CD94, LIR1, LIR2, LIR3, KIR2DL1, KIR2DL2 / 3, KIR3DL1, CEACAM1, LAIR1 and KLRG1, and / or (2) an antibody or fragment thereof targeting an NK inhibitory receptor such as HLA-E, HLA-F, HLA-G, cadherin, collagen, OCIL, sialic acid, PD-L1, PD-L2, CD155, CD112, CD113, Gal-9, FGL1, and NK inhibitory receptor binding domains contained therein.

10. The chimeric receptor of claim 8 , wherein the signaling domain is composed of one or more costimulatory domains.

11. The chimeric receptor of claim 8 , wherein the signaling domain further comprises a CD3ζ intracellular domain.

12. The chimeric receptor of any one of claims 8 to 11, wherein the costimulatory domain is selected from CD28 or the 4-1BB intracellular domain.

13. 13. A modified immune cell expressing the chimeric receptor of any one of claims 8 to 12, wherein expression of at least one MHC-associated gene is suppressed or silenced.

14. 14. The modified immune cell of claim 13, wherein the MHC-associated genes are selected from HLA-A, HLA-B, HLA-C, B2M, HLA-DPA, HLA-DQ, HLA-DRA, TAP1, TAP2, LMP2, LMP7, RFX5, RFXAP, RFXANK, CIITA, and combinations thereof.

15. 14. The modified immune cell of claim 13, further comprising at least one TCR / CD3 gene, the expression of which is inhibited or silenced, wherein the TCR / CD3 gene is selected from TRAC, TRBC, CD3γ, CD3δ, CD3ε, and CD3ζ.

16. 14. The modified immune cell of claim 13, further expressing a chimeric antigen receptor that targets a tumor antigen.

17. The modified immune cell of claim 13, selected from a T cell, a NK cell, a NKT cell, a macrophage, and a dendritic cell.

18. 6. An antibody conjugate comprising an antibody according to claim 1 or 2, or a multispecific antibody according to claim 4 or 5, and a second functional structure, wherein the second functional structure is selected from an Fc, a radioisotope, a structural moiety that extends half-life, a detectable marker and a drug.

19. A detection kit comprising an antibody according to claim 1 or 2, a multispecific antibody according to claim 4 or 5, a chimeric receptor according to any one of claims 8 to 12, or an antibody complex according to claim 18.

20. A pharmaceutical composition comprising an antibody according to claim 1 or 2, a multispecific antibody according to claim 4 or 5, a chimeric receptor according to any one of claims 8 to 12, an engineered immune cell according to any one of claims 13 to 17 or an antibody conjugate according to claim 18, and one or more pharma- ceutically acceptable excipients.

21. Use of an antibody according to claim 1 or 2, a multispecific antibody according to claim 4 or 5, a chimeric receptor according to any one of claims 8 to 12, a modified immune cell according to any one of claims 13 to 17, an antibody complex according to claim 18, or a pharmaceutical composition according to claim 20 in the preparation of a medicament for the prevention, treatment or diagnosis of a disease associated with NKG2A expression.

Citation Information

Patent Citations

  • Humanized anti-human NKG2A monoclonal antibody

    JP2011510047A

  • Selective elimination of invasive cells

    JP2014519522A

  • Compositions and methods for selective removal and replacement of hematopoietic stem cells

    JP2020510101A